
|Videos|November 10, 2018
Immunologic Biomarker Findings for mFOLFOX6 and Pembrolizumab in CRC
Author(s)Matthew Farren, PhD
Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses immunologic biomarker findings in a study of mFOLFOX6 plus pembrolizumab (Keytruda) in colorectal cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer
3
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
4
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
5



































